Efficacy News and Research

RSS

Smoked cannabis may be an effective treatment for spasticity

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity - a common and disabling symptom of this neurological disease.

15 May 2012

BioAlliance Pharma commences Livatag phase III trial in hepatocellular carcinoma

BioAlliance Pharma SA, a Company dedicated to orphan oncology products and specialty products, today announces the initiation of ReLive, its phase III clinical trial with Livatag(doxorubicin Transdrug), as scheduled in the advancement calendar of the project.

15 May 2012

Fibrocell submits azficel-T Phase II study protocol with FDA to treat restrictive burn scars

Fibrocell Science, Inc. announced today that is has submitted to the U.S. Food & Drug Administration (FDA) the company's Phase II clinical study protocol to evaluate the safety and efficacy of Fibrocell's lead therapy, azficel-T, in improving the range of motion, function and flexibility, in patients with existing restrictive burn scars.

15 May 2012

Breast brachytherapy with strut-based applicator effective for early-stage breast cancer

Breast brachytherapy with a strut-based applicator is a well-tolerated and effective treatment for early-stage breast cancer, according to a multi-site study with a median follow-up of four years. The research was presented as a scientific poster at the European Society for Radiology & Oncology (ESTRO) World Congress of Brachytherapy in Barcelona, May 10-12.

14 May 2012

Positive data from Piramal Healthcare’s BST-CarGel Phase III cartilage repair trial

Piramal Healthcare Bio-Orthopaedics, a division of Piramal Healthcare Limited, today announced that positive data from their pivotal (Phase III) clinical trial is being presented in 3 podium presentations as well as during an Industry Symposium at the 10th World Congress of the International Cartilage Repair Society (ICRS), May 12 to 15, in Montreal, Quebec, Canada.

14 May 2012

Top-line data from S.L.A. Pharma’s Nalcol Phase 2 study on OIC

S.L.A. Pharma AG has announced clinically and statistically significant top-line data from their Phase 2 double blind randomised placebo controlled study. The study was designed to evaluate the safety and efficacy of 4 doses of Nalcol, a novel oral formulation of naloxone, in treating opioid induced constipation (OIC) in patients with persistent non-cancer pain.

14 May 2012

New clinical trial to evaluate effectiveness of ABMT for PTSD

At Ease USA, a Nebraska organization dedicated to providing confidential post-traumatic stress disorder (PTSD) care for military families, has launched a clinical trial of a promising new therapeutic intervention at Creighton University.

14 May 2012

Study reveals variability in physician intentions and recommendations on HPV vaccination

Researchers at Moffitt Cancer Center surveyed 1,008 physicians seeking their knowledge, recommendation beliefs and information on their practices regarding the controversial human papillomavirus (HPV) vaccine, which is aimed at preventing cancers resulting from sexually transmitted HPV infection. Of the physicians surveyed, 112 provided additional comments at the conclusion of the survey.

14 May 2012

DIBH can spare hearts and lungs of breast cancer patients from radiation

Respiratory movement during radiotherapy makes it difficult to hit the right treatment target and this in turn can lead to an under-dose of radiation to the tumour, or a potentially toxic over-dose to the surrounding healthy tissue. Getting this right is a real challenge for the radiotherapist, but new techniques are helping to deliver the correct dose to the right place, the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31) will hear today.

14 May 2012

Event addresses FDA's recent draft guidelines for development of biosimilar products

Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.

14 May 2012

Study describes new compounds that inhibit PRMT1 enzyme

Scientists at The Scripps Research Institute have found the first chemical compounds that act to block an enzyme that has been linked to inflammatory conditions such as asthma and arthritis, as well as some inflammation-promoted cancers.

11 May 2012

Accelerated partial breast irradiation does not compromise survival

Using a concentrated, highly targeted dose of radiation to the breast has equally good results as irradiating the whole area, with no adverse effects on survival and a much better cosmetic outcome, Hungarian researchers have found.

11 May 2012

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the second wave of its LaunchTrends® Yervoy and Zelboraf report, in which 103 U.S.-based medical oncologists were surveyed about their current and expected treatment patterns in advanced melanoma.

11 May 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

ICD therapy significantly reduces mortality in patients with moderate heart failure

St. Jude Medical, Inc., a global medical device company, today announced results of the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) 10-Year Follow-up Study at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston. The study demonstrated implantable cardioverter defibrillator (ICD) therapy significantly reduces mortality for at least 11 years in patients with moderate heart failure (HF).

11 May 2012

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada(emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

11 May 2012

Macrocure's CureXcell Shows Strong Efficacy and Safety in Phase IV Hard-To-Heal Wounds Trial

Cell therapy demonstrates high rate of complete closure of hard-to-heal wounds, including diabetic foot (DFU) and venous ulcers.

10 May 2012

New technique measures brain activity in large populations of nerve cells

Researchers have developed a new technique which allows them to measure brain activity in large populations of nerve cells at the resolution of individual cells. The technique, reported today in the journal Nature, has been developed in zebrafish to represent a simplified model of how brain regions work together to flexibly control behaviour.

10 May 2012

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that analysis of U.S. longitudinal patient-level claims data reveals the use of Bristol-Myers Squibb's oral Abilify as a first-line therapy for newly diagnosed schizophrenia patients continues to grow.

10 May 2012

Resverlogix completes RVX-208 Phase 2b trial on CVD

Resverlogix Corp. is pleased to announce that dosing in SUSTAIN, a Phase 2b clinical trial to assess lipid trends and safety of RVX-208, has been completed on schedule.

10 May 2012

Efficacy News and Research

Smoked cannabis may be an effective treatment for spasticity

BioAlliance Pharma commences Livatag phase III trial in hepatocellular carcinoma

Fibrocell submits azficel-T Phase II study protocol with FDA to treat restrictive burn scars

Breast brachytherapy with strut-based applicator effective for early-stage breast cancer

Positive data from Piramal Healthcare’s BST-CarGel Phase III cartilage repair trial

Top-line data from S.L.A. Pharma’s Nalcol Phase 2 study on OIC

New clinical trial to evaluate effectiveness of ABMT for PTSD

Study reveals variability in physician intentions and recommendations on HPV vaccination

DIBH can spare hearts and lungs of breast cancer patients from radiation

Event addresses FDA's recent draft guidelines for development of biosimilar products

Study describes new compounds that inhibit PRMT1 enzyme

Accelerated partial breast irradiation does not compromise survival

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

ICD therapy significantly reduces mortality in patients with moderate heart failure

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Macrocure's CureXcell Shows Strong Efficacy and Safety in Phase IV Hard-To-Heal Wounds Trial

New technique measures brain activity in large populations of nerve cells

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

Resverlogix completes RVX-208 Phase 2b trial on CVD

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News